Elias A N, Barr R J, Rohan M K, Dangaran K
Department of Medicine, University of California at Irvine, USA.
Int J Dermatol. 1995 Apr;34(4):280-3. doi: 10.1111/j.1365-4362.1995.tb01598.x.
Antithyroid thioureylenes are effective agents in the oral and topical treatment of patients with chronic plaque psoriasis.
The effect of oral treatment with 6-n-propyl 2-thiouracil (propylthiouracil, PTU) and 2-mercapto 1-methyl imidazole (methimazole, MMI) on proliferating cell nuclear antigen (PCNA), and p53 protein expression was studied in patients with stable plaque psoriasis.
Following treatment with PTU and MMI, PCNA staining in psoriatic epidermis was significantly decreased. P53 was minimally expressed in untreated lesions, and treatment with PTU and MMI did not enhance p53 expression in the psoriatic lesions.
Since PCNA is a marker of cellular proliferation and p53 inhibits cellular cycling, some of the beneficial effects of PTU and MMI in psoriasis may depend on the ability of the drugs to impair cellular turnover, perhaps by binding to the triiodothyronine (T3) receptor. These effects may be in addition to the previously described effects of PTU and MMI as immune modulators and free radical scavengers.
抗甲状腺硫脲类药物是慢性斑块状银屑病患者口服及局部治疗的有效药物。
在稳定期斑块状银屑病患者中,研究口服6 - 正丙基 - 2 - 硫氧嘧啶(丙硫氧嘧啶,PTU)和2 - 巯基 - 1 - 甲基咪唑(甲巯咪唑,MMI)对增殖细胞核抗原(PCNA)及p53蛋白表达的影响。
PTU和MMI治疗后,银屑病表皮中的PCNA染色显著降低。p53在未治疗的皮损中表达极低,PTU和MMI治疗并未增强银屑病皮损中p53的表达。
由于PCNA是细胞增殖的标志物,而p53抑制细胞周期,PTU和MMI在银屑病中的一些有益作用可能取决于药物损害细胞更新的能力,或许是通过与三碘甲状腺原氨酸(T3)受体结合。这些作用可能是除了PTU和MMI作为免疫调节剂及自由基清除剂的先前描述作用之外的作用。